Basilea Pharmaceutica Ltd. is a biopharmaceutical company headquartered in Basel, Switzerland, listed on the SWX Swiss Exchange (SWX:BSLN). The company is focused on the discovery, development and commercialization of innovative medicines to satisfy high medical and patient needs in the hospital and specialty pharmaceutical setting.
Basilea has a fully integrated R&D organization and is currently building its sales and marketing organization in the U.S., Canada and major European markets. The company owns a broad and balanced late-stage product portfolio including novel treatments for resistant bacterial infections, systemic fungal infections, and severe skin diseases. The product pipeline comprises two drug candidates in pre-registration, one in clinical phase III as well as substantial innovative early-stage programs.
Canadian regulatory authority has accepted New Drug Submission for alitretinoin for review Basilea Pharmaceutica Ltd. (SWX:BSLN) announces that the Therapeutic Products Directorate (TPD) of Health Canada has accepted for review the New Drug Submission of oral alitretinoin for the treatment of severe refractory chronic hand eczema. more...
|
New scientific data on ceftobiprole and isavuconazole will be presented at ECCMID Basilea Pharmaceutica Ltd. highlighted today that new research and preclinical data on two late-stage product candidates ceftobiprole and isavuconazole will be presented at the upcoming European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Poster and oral presentations reflect the advanced stage of development of the broad-spectrum anti-MRSA antibiotic ceftobiprole. Additionally, publications on isavuconazole present further research results confirming the differentiated profile of the compound. more...
|
Basilea opens new phase III study in special patient populations for its broad-spectrum antifungal isavuconazole Basilea Pharmaceutica Ltd. (SWX:BSLN) announces that it has opened an additional phase III study to evaluate the efficacy and safety of isavuconazole in treating serious and life-threatening invasive fungal infections. Isavuconazole’s breadth of spectrum in vitro and its favorable pharmacokinetic profile formed the basis of this open label study. more...
|
Basilea implements holding structure Basilea Pharmaceutica Ltd. announces that changes to the Articles of Association approved by shareholders at the Annual General Meeting on March 19, 2008 and the implementation of a holding structure were executed on March 28, 2008. Operational business activities will be performed by the new subsidiary Basilea Pharmaceutica International Ltd. that is fully owned by the new holding company Basilea Pharmaceutica Ltd. more...
|
